EBC-129

N/A

Report date: 2025/06/23 15:39:15

First In Class

Base Information

Drug NameEBC-129

Drug Alias NameEBC-129EBC129

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-CEACAM6Anti-CEACAM5Tubulin polymerisation inhibitors

TargetsCarcinoembryonic antigen related cell adhesion molecule 6Carcinoembryonic antigen related cell adhesion molecule 5Tubulin

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSingaporeTaiwan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesExperimental Drug Development Centre

China Registration ClassN/A

Develop Information

Active CompaniesExperimental Drug Development Centre

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A